NCT01107665View on ClinicalTrials.gov

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Stage III MelanomaStage IV MelanomaUnresectable Melanoma
Interventions
DRUG

Pazopanib and Paclitaxel

Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of California, Irvine

OTHER

NCT01107665 - Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | Biotech Hunter | Biotech Hunter